Buscar
Heron Therapeutics Inc
HRTXAñadir a la lista de seguimiento
0.291USD
-0.008-2.68%
Cierre 09-23 16:00（ET）
55.08MCap. mercado
PérdidaP/E TTM
Acerca de Heron Therapeutics Inc Compañía
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Perfil de Heron Therapeutics Inc
Símbolo de cotizaciónHRTX
Nombre de la empresaHeron Therapeutics Inc
Fecha de salida a bolsaAug 26, 1987
Director ejecutivoCollard (Craig Alexander)
Número de empleados122
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 26
Dirección4242 Campus Point Court, Suite 200
CiudadCARY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Teléfono18582514400
Sitio Webhttps://www.herontx.com/
Símbolo de cotizaciónHRTX
Fecha de salida a bolsaAug 26, 1987
Director ejecutivoCollard (Craig Alexander)
Ejecutivos de Heron Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
836.00K
+11.80%
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
836.00K
+11.80%
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
836.00K
+11.80%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
270.88K
+7.69%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
270.88K
+7.69%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
270.88K
+7.69%
Dr. William P. (Bill) Forbes, Pharm.D.
Dr. William P. (Bill) Forbes, Pharm.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
241.11K
+8.11%
Dr. William P. (Bill) Forbes, Pharm.D.
Dr. William P. (Bill) Forbes, Pharm.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
241.11K
+8.11%
Dr. William P. (Bill) Forbes, Pharm.D.
Dr. William P. (Bill) Forbes, Pharm.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
241.11K
+8.11%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
87.18K
-40.41%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
836.00K
+11.80%
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
836.00K
+11.80%
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
836.00K
+11.80%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
270.88K
+7.69%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
270.88K
+7.69%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
270.88K
+7.69%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Heron Therapeutics Inc?
Los cinco principales accionistas de Heron Therapeutics Inc son: Mr. Craig Alexander Collard
¿Cuántas instituciones poseen acciones de Heron Therapeutics Inc (HRTX)?
A fecha de 2026Q1, 354 instituciones poseen acciones de Heron Therapeutics Inc, con un valor de mercado combinado de aproximadamente 169.55M, lo que representa el 90.02% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -8087547.00.
¿Cuál es la mayor fuente de ganancias de Heron Therapeutics Inc?
El 2026Q1, el segmento empresarial CINVANTI generó la ganancia más alta para Heron Therapeutics Inc, ascendiendo a 21.79M y representando el 57.86% de la ganancia total.